Study was put on hold then out of Medical Plan therefore cancelled

This single arm study will assess the efficacy and safety of first line combination treatment with Avastin + docetaxel in patients with HER2 negative metastatic breast cancer.Patients will receive Avastin (15mg/kg iv every 3 weeks) plus docetaxel (75mg/m2 every 3 weeks for 6 cycles). The anticipated time on study treatment is until disease progression, and the target sample size is 100 individuals.

Inclusion Criteria:

• male and female patients, >=18 years of age;
• stage IV, HER2 negative metastatic breast cancer;
• candidate for taxane-based therapy;
• ECOG performance status 0-2.

Exclusion Criteria:

• prior chemotherapy for metastatic breast cancer;
• concomitant primary malignant disease, except for adequately treated cervical cancer in situ, or basal or squamous cell skin cancer within last 5 years;
• suspicion of CNS metastasis;
• clinically significant cardiovascular disease.